This indicates that MGL inhibition may protect platelets from activation by high levels of endocannabinoids and that pharmacological CBR1 and CBR2 ligands will have no effect on platelets and platelet-dependent progression and complications of cardiovascular disease [14].Platelets can be targeted by endocannabinoid signaling as they express both CBR1 and CBR2 [15]. This evidence concerns the gene CBR1 and cardiovascular disorder.